Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.70 |
| ▸ | MAOB | P27338 | 3/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016108 | 1.00 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15200609 | 1.00 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL16355420 | 1.00 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL17984453 | 1.00 | KDM1A (0.70) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL19609152 | 0.87 | KDM1A (0.61) | KDM1AMAOBMAOAHDAC6 | |
| SCHEMBL16019177 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL17718446 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15096181 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL15235894 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 | |
| SCHEMBL17718439 | 0.87 | KDM1A (0.71) | KDM1AMAOBMAOATLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109153636-A | Cyclopropyl-amide compound as dual LSD1/HDAC inhibitor | 朱比连特比利斯有限公司 | 2019-01-04 | — | — | CN | disclosed |
| EP-2814321-B1 | NEMATICIDAL CIS (HETERO)ARYLCYCLOPROPYLCARBOXAMIDE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2018-09-26 | — | — | EP | disclosed |
| WO-2017195216-A1 | CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS | JUBILANT BIOSYS LIMITED (IN) | 2017-11-16 | — | — | WO | disclosed |
| US-9408392-B2 | Compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-20140378461-A1 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-12-25 | — | — | US | disclosed |
| EP-2814321-A2 | NEMATICIDAL CIS (HETERO)ARYLCYCLOPROPYLCARBOXAMIDE DERIVATIVES | Syngenta Participations AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013120940-A2 | NOVEL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7253285-B2 | Thiazolinone 4-monosubstituted quinolines | HOFFMANN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1797085-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. Hoffmann-Roche AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CHEN LI | 2006-03-23 | — | — | US | disclosed |
| WO-2006029861-A1 | THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063805-A1 | Thiazolinone 4-monosubstituted quinolines | CDK1, CDK14, CDK17 | KDM1A 1498/4885MAOB 4298/4885MAOA 4468/4885 |
| US-20140378461-A1 | NOVEL COMPOUNDS | CYP1B1, DDT, CYP51A1 | KDM1A 1147/4885MAOB 1203/4885MAOA 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.